Embecta Corp.

Diabetes company embecta, spun out of BD in early 2022, has a decades-long history of supplying manual insulin pen needles and syringes, among other accessories. Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes.The fully disposable device includes a 300-unit insulin reservoir, which embecta said could last most users with Type 2 diabetes about three days, based on the average amounts taken by people relying on multiple daily injections to control their blood sugar levels.According to the company, although about 90% of people with diabetes have Type 2, many of today’s automated delivery devices were first designed for people with Type 1—which typically requires smaller daily doses of insulin—resulting in unmet needs within the population of users.For example, a study from embecta found that a 300-unit reservoir would last three days for 64% of adults with Type 2 diabetes, while carrying 200 units would only meet the needs of 38%.“FDA clearance of our disposable insulin delivery system has been a top strategic priority for our team since launching embecta as an independent company, and achieving this milestone through strong execution exemplifies our commitment to making life better for the growing number of people living with diabetes,” CEO Dev Kurdikar said in a statement.The diabetes company, spun out of BD in early 2022, has a decades-long history of supplying manual insulin pen needles and syringes, among other accessories.The new wearable, which received a 510(k) clearance as an alternate controller-enabled insulin infusion pump, also connects with a dedicated, touchscreen-operated controller unit. Looking ahead, Embecta is developing a closed-loop version of its tubeless patch pump, which would automatically respond to readings from a continuous glucose monitor; the company said it plans to submit the system to the FDA for review in the future.For the insulin-dosing algorithm, the company has been collaborating with diabetes software developer Tidepool. The former Fierce Medtech Fierce 15 winner received an agency clearance for its own artificial pancreas app in early 2023.Tidepool’s software was also recently featured in a new automated insulin pump designed by Dean Kamen’s Deka Research & Development, which will launch commercially through Sequel Med Tech for people with Type 1 diabetes.Embecta’s FDA green light comes shortly after the agency’s first clearance for an automated insulin pump in Type 2 diabetes, with Insulet’s tubeless, patch-based Omnipod 5.

DUBLIN--( BUSINESS WIRE )--The "Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials" report has been added to ResearchAndMarkets.com's offering. The Global Emerging Insulin Drug and Delivery Technologies Market was valued at $55.8 Billion in 2023 and is and is expected to reach $88.9 Billion in 2028, rising at a CAGR of 9.8%. This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report's patent analysis focuses on developments in Japan, Europe, and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories. The Report Includes 57 data tables and 83 additional tables An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application, and region A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets Discussion of the ESG developments and how they impact corporate performance, ratings and matrices, and consumer attitude, as well as the ESG practices of leading pharma and biotech companies Review of the key patent grants/publications for insulin as a drug, along with its delivery methods Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies Profiles of the leading market players The analysis revealed that the fastest-growing market segment is smart pens, which is expected to grow at a predicted CAGR of 12.6% during the forecast period. The insulin syringes and vials segment is expected to have the slowest growth rate, a CAGR of 8.7%. The increase in prevalence of diabetes mellitus, including type 2 diabetes worldwide, the most prevalent form, has reached epidemic levels. Concurrently, instances of type 1 diabetes mellitus are on the rise, albeit to a lesser extent. These escalating trends raise significant alarm, impacting not only those affected but also governments and healthcare providers, as the economic ramifications of diabetes are substantial. They involve the direct burden of managing the disease and its common and often catastrophic complications, including cardiovascular disease, peripheral neuropathy and blindness. Ensuring timely diagnosis of diabetes and delivering efficient treatment are priorities for governments and healthcare organizations. As the prevalence of diabetes continues to rise and diagnostic methods advance, the existing market for insulin drug and delivery technologies is expected to expand significantly. Consequently, diabetes holds substantial commercial importance for both the manufacturers of treatment drugs and the producers of monitoring devices. For companies in this sector to strengthen their market position, they require precise and current evaluations of the present magnitude of the diabetes epidemic, as well as its probable trajectory over the upcoming five years, and the potential impact of insulin drug and delivery devices and technical developments now in the pipeline. The market for insulin drug and delivery technologies will continue to grow significantly in many areas, notably regulatory compliance. Key Attributes: Report Attribute Details No. of Pages 158 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $55.8 Billion Forecasted Market Value (USD) by 2028 $88.9 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Types of Diabetes Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Mellitus or Hyperglycemia in Pregnancy Impaired Glucose Tolerance and Impaired Fasting Glucose Epidemiology of Diabetes Gender Distribution Regional Disparities Market Dynamics Snapshot Factors Affecting the Market Market Drivers Market Restraints Chapter 4 Global Market for Emerging Insulin Drug and Delivery Technologies, by Type Technological Advances in Insulin Syringes Insulin Delivery Pen Devices Disposable Insulin Pens Reusable Insulin Pens Technological Advances in Insulin Drug and Delivery Pen Devices External Insulin Pumps Technological Advances in Insulin Pump Systems Implantable Insulin Pumps Closed-Loop Artificial Pancreas Bionic Pancreas Smart Pens Chapter 5 Global Market for Emerging Insulin Drug Delivery Devices, by Application Chapter 6 Global Market for Insulin Drug Delivery Devices, by Region Chapter 7 Regulatory Landscape Chapter 8 Sustainability in the Insulin Drug and Delivery Market: An ESG Perspective Chapter 9 Emerging Technologies Patient Outcomes Beyond Glucose Control Chapter 10 Patent Analysis Chapter 11 M&A and Venture Funding Outlook Chapter 12 Competitive Landscape Chapter 13 Company Profiles AstraZeneca B. Braun BD Cardinal Health Debiotech Diabeloop Emperra E-Health Technologies Embecta Corp. F. Hoffmann-La Roche Insulet Corp. Johnson & Johnson Services Lifescan Ip Holdings Lilly Medtronic Novo Nordisk Nugen Medical Devices Owen Mumford Sanofi Sooil Developments Tandem Diabetes Care Terumo Corp. Ypsomed For more information about this report visit https://www.researchandmarkets.com/r/8ravs1 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, March 6, 2024 /PRNewswire/ -- The "Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials" report has been added to ResearchAndMarkets.com's offering. The Global Emerging Insulin Drug and Delivery Technologies Market was valued at $55.8 Billion in 2023 and is and is expected to reach $88.9 Billion in 2028, rising at a CAGR of 9.8%. This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report's patent analysis focuses on developments in Japan, Europe, and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories. The Report Includes 57 data tables and 83 additional tables An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application, and region A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets Discussion of the ESG developments and how they impact corporate performance, ratings and matrices, and consumer attitude, as well as the ESG practices of leading pharma and biotech companies Review of the key patent grants/publications for insulin as a drug, along with its delivery methods Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies Profiles of the leading market players The analysis revealed that the fastest-growing market segment is smart pens, which is expected to grow at a predicted CAGR of 12.6% during the forecast period. The insulin syringes and vials segment is expected to have the slowest growth rate, a CAGR of 8.7%. The increase in prevalence of diabetes mellitus, including type 2 diabetes worldwide, the most prevalent form, has reached epidemic levels. Concurrently, instances of type 1 diabetes mellitus are on the rise, albeit to a lesser extent. These escalating trends raise significant alarm, impacting not only those affected but also governments and healthcare providers, as the economic ramifications of diabetes are substantial. They involve the direct burden of managing the disease and its common and often catastrophic complications, including cardiovascular disease, peripheral neuropathy and blindness. Ensuring timely diagnosis of diabetes and delivering efficient treatment are priorities for governments and healthcare organizations. As the prevalence of diabetes continues to rise and diagnostic methods advance, the existing market for insulin drug and delivery technologies is expected to expand significantly. Consequently, diabetes holds substantial commercial importance for both the manufacturers of treatment drugs and the producers of monitoring devices. For companies in this sector to strengthen their market position, they require precise and current evaluations of the present magnitude of the diabetes epidemic, as well as its probable trajectory over the upcoming five years, and the potential impact of insulin drug and delivery devices and technical developments now in the pipeline. The market for insulin drug and delivery technologies will continue to grow significantly in many areas, notably regulatory compliance. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Types of Diabetes Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Mellitus or Hyperglycemia in Pregnancy Impaired Glucose Tolerance and Impaired Fasting Glucose Epidemiology of Diabetes Gender Distribution Regional Disparities Market Dynamics Snapshot Factors Affecting the Market Market Drivers Market Restraints Chapter 4 Global Market for Emerging Insulin Drug and Delivery Technologies, by Type Technological Advances in Insulin Syringes Insulin Delivery Pen Devices Disposable Insulin Pens Reusable Insulin Pens Technological Advances in Insulin Drug and Delivery Pen Devices External Insulin Pumps Technological Advances in Insulin Pump Systems Implantable Insulin Pumps Closed-Loop Artificial Pancreas Bionic Pancreas Smart Pens Chapter 5 Global Market for Emerging Insulin Drug Delivery Devices, by Application Chapter 6 Global Market for Insulin Drug Delivery Devices, by Region Chapter 7 Regulatory Landscape Chapter 8 Sustainability in the Insulin Drug and Delivery Market: An ESG Perspective Chapter 9 Emerging Technologies Patient Outcomes Beyond Glucose Control Chapter 10 Patent Analysis Chapter 11 M&A and Venture Funding Outlook Chapter 12 Competitive Landscape Chapter 13 Company Profiles AstraZeneca B. Braun BD Cardinal Health Debiotech Diabeloop Emperra E-Health Technologies Embecta Corp. F. Hoffmann-La Roche Insulet Corp. Johnson & Johnson Services Lifescan Ip Holdings Lilly Medtronic Novo Nordisk Nugen Medical Devices Owen Mumford Sanofi Sooil Developments Tandem Diabetes Care Terumo Corp. Ypsomed For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets